KPF
GILD icon

K2 Principal Fund’s Gilead Sciences GILD Stock Holding History

K2 Principal Fund’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,000
Closed -$396K – 297
2016
Q3 		$396K Buy
+5,000
New +$406K 0.04% 213

Other funds holding GILD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

K2 Principal Fund's GILD Position: Q4 2016 in Review

K2 Principal Fund sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 10,700 shares — an estimated $847K sold.

K2 Principal Fund first reported a position in GILD in Q1 2016 and held it in 3 quarters. The position peaked at $2.95M in Q1 2016. 1,572 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

  • K2 Principal Fund reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
  • K2 Principal Fund sold 10,700 Gilead Sciences shares in Q4 2016, an estimated $847K.
  • K2 Principal Fund first reported a position in Gilead Sciences in Q1 2016 and held it in 3 quarters.
  • K2 Principal Fund's Gilead Sciences position peaked at $2.95M in Q1 2016.
  • 1,572 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on K2 Principal Fund's 13F filing for Q4 2016, filed 15 Feb 2017.